Navigation Links
Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine

SAN FRANCISCO, April 11, 2007 /PRNewswire-FirstCall/ -- Vical Incorporated today announced that a seasonal influenza vaccine formulated with the company's Vaxfectin(TM) adjuvant generated up to 60-fold higher antibody responses than an unformulated vaccine at the same dose in a recently completed study in mice. Formulation of sanofi pasteur's Fluzone(R) commercial vaccine with Vaxfectin(TM) also allowed a nearly 10-fold reduction in vaccine dose while generating equivalent or better antibody responses compared with unformulated vaccine, even at the lowest doses tested. Alain P. Rolland, Pharm.D., Ph.D., the company's Senior Vice President of Product Development, presented the data at the Drug Delivery 2007 meeting (San Francisco, April 9 - 11).

Vical is developing its own Vaxfectin(TM)-formulated DNA vaccine designed to protect against emerging strains of influenza virus that have the potential to cause a pandemic. In previously reported studies conducted at St. Jude Children's Research Hospital, Vical's lead Vaxfectin(TM)-formulated, DNA vaccine candidate provided 100% protection in mice and ferrets against lethal challenges with a highly pathogenic strain of H5N1 influenza virus. Initial human testing of Vical's influenza DNA vaccine is expected to begin in the second half of 2007.

Vical tested the Vaxfectin(TM) adjuvant with Fluzone(R) seasonal influenza vaccine to evaluate its potential to ease the anticipated shortage of stockpiled pandemic influenza vaccine and the limited global vaccine manufacturing capacity. In separate studies conducted by others, stockpiled sanofi pasteur H5N1 pandemic influenza vaccine with no adjuvant achieved target levels of antibodies in less than half the subjects after two 90 mcg doses -- a total of six times the normal 15 mcg dose of each strain that provides 75% to 90% protection against seasonal influenza.

The new Fluzone(R) study data confirm and expan
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
2. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
3. New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
4. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
5. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
6. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
7. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
8. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
9. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
10. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
11. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
(Date:10/9/2008)...Call/ -- Diamyd Medical reports,that the world,s m...ournal,of Medicine, has published an article with ...diabetes vaccine for type 1 diabetes., (Logo: ht... ), The article is now available on the journal,s...rint on October 30. It presents the,results of the...
(Date:10/8/2008)...osmetics and Chemicals Testing, ASHLAND, Mass., O...,that results of a recently completed US and Europ...n MatTek,s EpiDerm in vitro human skin tissue,equi... sensitivity and,specificity for EpiDerm to be acc... for determining human skin irritation by the Euro...
(Date:10/8/2008)...rch That May Offer New Hope to,Heart Failure Patie...over 3,000 people are,waiting for a heart transpla...those will receive a transplant. Now, pioneering r... the way for how to treat congestive heart,failure...ease, go to:, http://www.prnewswire.com/mnr/ahi/35...
(Date:10/8/2008)...xpand Testing Using Cellular .... 8 /- Wild Blueberry antioxidant,res...rom a new study,showing Wild Blueberries outperfor...ples, bananas, red grapes and strawberries in an e...ty (CAA) assay. New research,published in the curr...
Breaking Medicine Technology:Diamyd(R) Study Published in Prestigious New England Journal of Medicine 2Diamyd(R) Study Published in Prestigious New England Journal of Medicine 3Diamyd(R) Study Published in Prestigious New England Journal of Medicine 4MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 3Wild Blueberries Take Top Spot in New Antioxidant Research Study 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 3UT Southwestern urologist uses Botox to treat debilitating condition 7591 1UT Southwestern urologist uses Botox to treat debilitating condition 7591 2Good Clean Foods New Line of All Natural Simmer Sauces for Chicken Hits Market Shelves 7589 1Good Clean Foods New Line of All Natural Simmer Sauces for Chicken Hits Market Shelves 7589 2Good Clean Foods New Line of All Natural Simmer Sauces for Chicken Hits Market Shelves 7589 3Rising food prices threaten worlds poor people 1461 1Rising food prices threaten worlds poor people 1461 2Rising food prices threaten worlds poor people 1461 3Rising food prices threaten worlds poor people 1461 4Heska to Present at New York Society of Security Analysts Biotech Specialty Pharma Conference 7586 1
...School and Daycare Study Outcomes Suggest,Vaccin...or,Community at Large, TORONTO, May 08, 2007 /...ed today research results showing that use of FluM...) in daycare and school,settings may help reduce...yses applied to outcomes observed in previously co...
...USINESS WIRE)--May 9, 2007 - Regeneron,Pharmaceuti...,results from several studies evaluating the VEGF ...cular degeneration (wet AMD) and,diabetic macular ...ek at the annual meeting of the Association for Re...a reported at the meeting,from a pre-planned inter...
Other Medicine Technology:Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 2Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 3Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 4Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 5Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 6Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 7Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 8VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting 2VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting 3VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting 4VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting 5
(Date:10/10/2008)...OBI, Kenya, Oct. 10 /PRNewswire-USNewswire/ -- Pub...a global meeting convened to make,decisions on the...ronment.,On 6-10 October 2008, the 2nd UNEP(2) Ope... the elements that would form part of a global fra...erning Council (GC) in February,2009, where it wil...
(Date:10/10/2008)... The Healthcare Technology Evolu... Exton, PA (PRWEB) Septemb...Chapters of the national Healthcare Information Ma...ces to bring regional health information technolog...nference entitled The Healthcare Technology Evolut...
(Date:10/10/2008)... YORK, Oct. 10 /PRNewswire/ -- The Johns Hopkins U...multimedia educational program,"Optimizing Adjuva...eatment,Selection," to present recent key research...tment., In recent years, advancements in the trea...c and biologic treatment combinations that are,inc...
(Date:10/9/2008)...ding Melanoma Specialists Will Give Accredited Cou...agement of Melanoma, To be held November 1, 2008 ... CONCORD, Mass., Oct. 9 /PRNewswire-USNewswire/ --...ston University School of Medicine are,co-sponsori... Education,(ACCME) course to update non-dermatolog...
Breaking Medicine News(10 mins):Health News:Elements for a UN Global Framework on Mercury Agreed to 2Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Paul Sullivan's Legacy: An Early Warning Program for Detecting Melanoma Before It's Too Late 2
...s of Indian origin obtained an unprecedented emerg... down by the Department of Health. The new law pot...veral non-European doctors in the current round of...rvice (NHS). The injunction has been obtained aga...
...a government has planned to introduce an amendment...mpler for mentally ill patients to be committed to...ications. This proposed legislation was received ...rters of the society. While the advocates of the m...
...tralian Fashion Week activities commence around th...nment to work with the fashion industry and health...l the body image promoted by fashion models. Such...lf esteem and poor health among people who are inf...
...dition of immunotherapy to chemotherapy for malign...urvival rates, researchers have //found, and patie..., when the two treatments are combined. Malignant...n the cells responsible for skin color, and is one...
Other Medicine News:Health News:UK Indian Doctors Obtain Injunction Against New Rule 2Health News:Immunotherapy Does Not Prolong Life When Skin Cancer Spreads 2Health News:Immunotherapy Does Not Prolong Life When Skin Cancer Spreads 3
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
Medicine Products: